Minerva Neurosciences’ (NERV) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $5.00 target price on the biopharmaceutical company’s stock.

Separately, StockNews.com assumed coverage on Minerva Neurosciences in a research report on Saturday, February 22nd. They issued a “sell” rating for the company.

Minerva Neurosciences Stock Performance

NERV stock opened at $1.75 on Wednesday. Minerva Neurosciences has a one year low of $1.71 and a one year high of $3.69. The firm’s fifty day moving average is $2.16 and its 200 day moving average is $2.39. The firm has a market cap of $12.24 million, a PE ratio of -3.98 and a beta of 0.12.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.49. Research analysts predict that Minerva Neurosciences will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of Minerva Neurosciences

A hedge fund recently raised its stake in Minerva Neurosciences stock. Citadel Advisors LLC raised its holdings in shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,764 shares of the biopharmaceutical company’s stock after buying an additional 8,525 shares during the quarter. Citadel Advisors LLC owned about 0.37% of Minerva Neurosciences worth $57,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 34.56% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.